Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

[1]  L. Tokgözoğlu,et al.  Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach. , 2022, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[2]  J. Pinilla-Ibarz,et al.  Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. , 2020, Blood advances.

[3]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[4]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[5]  R. Foà,et al.  Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. , 2019, International journal of cardiology.

[6]  R. Foà,et al.  Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart , 2019, Hematological oncology.

[7]  Deepak L. Bhatt,et al.  Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease , 2019, JAMA.

[8]  Z. Korade,et al.  Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol[S] , 2018, Journal of Lipid Research.

[9]  Martin C. Müller,et al.  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.

[10]  J. Jukema,et al.  The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model , 2018, Front. Cardiovasc. Med..

[11]  G. Rosti,et al.  Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission , 2018, Front. Oncol..

[12]  M. Breccia,et al.  Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option , 2018, Clinical Drug Investigation.

[13]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[14]  J. Borén,et al.  The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity , 2016, Current opinion in lipidology.

[15]  M. Baccarani,et al.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia , 2016, Leukemia.

[16]  C. Carcassi,et al.  Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. , 2015, Experimental hematology.

[17]  J. Guyton,et al.  Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy , 2013, The Annals of pharmacotherapy.

[18]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[19]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[20]  L. Martorana,et al.  Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia , 2008, Leukemia.

[21]  R. Krauss,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease , 2018 .

[22]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[23]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.